GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for stomach cancer: triple therapy shows promise
Disease control Not yet recruitingThis study tests a new treatment for people with advanced stomach cancer that has not spread to other parts of the body or has spread a little. The treatment combines two immunotherapy drugs, chemotherapy, and targeted radiation. The goal is to see if this combination can shrink …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE4 • Sponsor: Huazhong University of Science and Technology • Aim: Disease control
Last updated May 26, 2026 12:10 UTC
-
New injection plus chemo shows promise in early trial for stomach and esophagus cancers
Disease control Not yet recruitingThis study tests whether injecting a new treatment called RP2 directly into tumors, along with standard chemotherapy (FLOT), is safe and works better than chemotherapy alone before surgery. It involves 34 adults with stage 2 or higher stomach or esophagus cancer that hasn't sprea…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated May 26, 2026 12:09 UTC
-
New hope for stomach cancer patients when first treatment fails
Disease control Not yet recruitingThis study tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer whose first treatment stopped working or caused side effects. The goal is to see if this new combo can s…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: NA • Sponsor: Qingxia Li • Aim: Disease control
Last updated May 26, 2026 12:08 UTC
-
New combo therapy aims to wipe out stomach cancer before surgery
Disease control Not yet recruitingThis study tests whether adding the experimental drug IBI343 to standard chemotherapy and an immunotherapy drug can improve outcomes for people with a specific type of advanced stomach or gastroesophageal junction cancer. About 90 participants whose tumors have a protein called C…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
New hope for advanced stomach cancer: targeted drug enters final testing phase
Disease control Not yet recruitingThis study tests a new drug called BL-M05D1 in people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2) and has stopped responding to initial treatment. About 438 adults will be randomly assigned to receive either BL-M05D1 or a standa…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
Experimental pill tested on patients with advanced cancers
Disease control Not yet recruitingThis is the first human study of an experimental oral drug called ACC-1898 for adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and understand how the body processes the drug. Participants will take dail…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: AccSalus Biosciences, Inc. • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC